{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-23-000028","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.821500+00:00","generated_at":"2026-06-15T02:43:52.204563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Humacyte Q1 net loss $37M; secures second RMAT for HAV in vascular trauma, plans BLA filing in 2023","bullets":["Net loss of $37.0M in Q1 2023 vs $19.8M in Q1 2022; cash & investments $131.7M at March 31, 2023.","Received second FDA RMAT designation for HAV in urgent arterial repair after extremity vascular trauma.","Completed enrollment in Phase 3 hemodialysis access trial (240 patients); top-line results expected in 2024.","Plans to file BLA with FDA later in 2023 for HAV in vascular trauma; V005 trial enrolled 66 patients.","Subsequent to Q1, secured up to $160M funding arrangement with Oberland Capital to fund operations past potential approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-23-000028","json":"https://secwatch.observer/filing/0001818382-23-000028.json","markdown":"https://secwatch.observer/filing/0001818382-23-000028.md","text":"https://secwatch.observer/filing/0001818382-23-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000028/0001818382-23-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000028/huma-20230512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:43:52.204563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21a9806bc76b43796f53fc16ad64af1d09325e2d","claim":"Humacyte, Inc. reported the first quarter of 2023 results: net income $37.0 million.","evidence_excerpt":"Net loss was $37.0 million for the first quarter of 2023, compared to $19.8 million for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000028/0001818382-23-000028-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Net income","value":"$37.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}